RxDoctor Payments Data

Kira Przybylko, MD

Obstetrics & Gynecology · Lawrenceville, NJNPI 1962474841

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,400 of the $5,699 with a category attached, or 94.7%. Mimedx Group, Inc. accounts for 94.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $3,600, more than ten times the $229 reported in 2019. Among obstetrics & gynecology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,699in general payments, 2019–2025

Across 39 payments — averaging $146.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$5K
  • AbbVie$110
  • Bayer$44
  • Pfizer$43
  • Celularity Inc.$16
  • Sage Therapeutics, LLC$15
  • plus $71 from 6 others
$82,620in research payments, 2019–2025

Across 3 payments — averaging $27,540 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$83K

What the payments were for

  • Consulting fees$5,40095%
  • Food & beverage$2995%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,699 in reported general payments places this provider in the 90th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

See all obstetrics & gynecology providers in New Jersey

Medicare billing

Part B allowed, 2024
$22,907
Medicare patients
114
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated25$11,690
EstringEstradiol11$5,597
Estradiol62$4,244
Risedronate Sodium14$1,802
Raloxifene Hcl26$1,120
ProgesteroneProgesterone, Micronized13$346
ValacyclovirValacyclovir Hcl16$304
Clobetasol Propionate11$253
Misoprostol13$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$43$17,28736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

Other obstetrics & gynecology in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →